This open-label trial (n=10) serves as a preliminary study to see if psilocybin (in combination with psychotherapy) may help treat anxiety, depression and chronic pain (demoralization) in cancer survivors.
Compound Psilocybin
Country United States of America
Visit trial
Status
Not yet recruiting
Results Published
No
Start date
31 August 2022
End date
31 August 2023
Chance of happening
100%
Phase
Phase I
Design
Open
Type
Interventional
Generation
First
Participants
10
Sex
All
Age
26- 99
Therapy
No
Trial Details
This phase I trial evaluates the side effects of psilocybin and how well it works under supportive care conditions in cancer survivors living with demoralization and chronic pain. Cancer patients often experience demoralization, which is characterized by feelings of hopelessness, loss of meaning, and existential distress. Psilocybin psychotherapy, together with multidisciplinary palliative and supportive care, may help treat the anxiety, depression, and chronic pain felt by cancer survivors - defined here as cancer patients from time of diagnosis through the end-of-life.NCT Number NCT05506982
Sponsors & Collaborators
Emory UniversityEmory University has recently launched the Center for Psychedelics and Spirituality (ECPS). The centre will combine expertise in psychiatry with spiritual health to better understand the therapeutic promise of psychedelics as medicine.